Navigation Links
A New Strategy to Control Breast Cancer

A recent study finds that, TACE inhibitors currently developed for treating rheumatoid arthritis can also be employed to control proliferation of tumor cells. TACE is// strongly present in a form of breast cancer, which responds poorly to current therapies.

TACE (tumor necrosis factor-alpha-converting enzyme) acts like a “molecular scissors” that releases a pair of ligands, called Amphiregulin and TGF-alpha, from the cell surface. These ligands activate EGFR.

EGFR, which stands for Epidermal Growth Factor Receptor, is the protein on the outer surface of a cell that is activated by EGF and related growth factors and signals for the cell to divide. Given that one of the hallmarks of cancer is cell division run amok, the reduction of high levels of EGFR activity has long been a primary target for anti-cancer drug development. So far, however, drugs aimed at directly inhibiting EGFR activity have met with only limited success in the cancer clinic, primarily in a small number of lung cancers.

Bissell and Kenny, researchers with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have demonstrated that by targeting TACE (also known as ADAM17) with either molecular inhibitors or short interfering RNAs (siRNAs) that silence the TACE gene, the shedding of Amphiregulin and TGF-alpha ligands could effectively be blocked.

This also resulted in the inhibition of EGFR signaling and the reversion of malignant characteristics in tumor cells. It is the first reported use of protease inhibitors to stop breast cancer cell proliferation and restore the normal breast tissue structure.

Tumor cells, says Bissell, exist in the same microenvironment as healthy cells and must therefore appropriate normal physiological processes to facilitate their growth and spread. This idea can open up potential new avenues and targets for diagnostic and therapeutic applications.

“Because of this,
'"/>




Page: 1 2

Related medicine news :

1. Novel Strategy To Combat Alzheimer’s Disease
2. "Defensive Pessimism" Before Exam Results Not a Good Strategy
3. WHO Devises New Global Strategy To Fight Tuberculosis
4. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
5. West Nile Virus Can Be Tackled By New Strategy
6. Australia Set To Implement A national Strategy Tackle Cannabis Abuse
7. Clement Urged to Plot a National Pharmaceutical Strategy
8. New Preventive Strategy to Fight Childhood Obesity
9. Rae unveils Health-care Strategy
10. A Promising New Vaccination Strategy for Late-Stage Melanoma
11. Effective Strategy Against Bird flu-Spainish Flu Vaccine Raises Hopes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Strategy Control Breast Cancer

(Date:12/2/2008)...NGTON -- A new report from the Institute of Medici...ours and workloads to decrease the chances of fati...ning environment for these doctors in training. T...dents, work hours from the maximum average of 80 p...ate Medical Education (ACGME) in 2003, but rather ...
(Date:12/2/2008)... SAN DIEGO, Dec. 2 Stroller Stri...exercise program for new moms and their babies, ha...re for more than 40 years, has signed on as the co...ew partnership will strengthen the companies, shar.... , , "We are thrilled to have Pampers as o...
(Date:12/2/2008)... Comparator Study to Evaluate Efficacy of Commerci...WOODCLIFF LAKE, N.J., Dec. 2 Eisai... it plans to initiate the first clinical trial eva... injection) compared to Vidaza(R) (azacitidine) in...2 or high-risk myelodysplastic syndromes (MDS), a ...
(Date:12/2/2008)... Tenn., Dec. 2 Emdeon, a leading p...olutions for the healthcare industry,announced t...business,efficiency in healthcare. Emdeon unveile...ushealthcareindex.com ) to establish a national re... from a paper-based and phone-based,system to an ...
Breaking Medicine News(10 mins):Health News:Revised hours and workloads for medical residents needed to prevent 2Health News:Revised hours and workloads for medical residents needed to prevent 3Health News:Stroller Strides(R) Signs Pampers(R) as Premier Sponsor for 2009 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 2Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 3Health News:Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare 4
...pmental Biology, members of Dr. John Herr’s labora...eport the discovery// of a new protein within a sp...contraceptive drugs. “There’s considerable intere...es,” said Herr, who heads UVa’s Center for Researc...
...Medical Center have developed the first gene chip,...diagnosis of at// least five hereditary liver dise...causes of jaundice in children and adults, and pot...nt options. The Cincinnati Children's study resul...
...ad, medical science miracles will be a fact - tech...treatments will stand to// reshape the lives of pe...planning department at Eastern Virginia Medical Sc...sh Medical Journal based on these technologies. &...
...ck pain are effective, a new review of studies has...ological outcomes such as// depression and health-...’ experience of pain. “Because this analysis was...ative than previous reviews, we have the best evid...
Other Medicine News:Health News:Male Contraception: Discovery Stirring Interest Among Scientists, Drug Developers 2Health News:First Gene Chip Discovered by Cincinnati Researchers 2Health News:First Gene Chip Discovered by Cincinnati Researchers 3Health News:Medical Science Miracles – Coming Your Wa 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 3
(Date:11/25/2008)...ss Survival of Patients Receiving Litx versus Stan...ular Carcinoma , , BELLEVUE, Wash., Nov. 25...O) today announced the completion of enrollment in... Therapy(TM) (Litx(TM)) as a treatment for unresec...s hepatoma or primary liver cancer. , , The...
(Date:11/24/2008)...ewswire/ -- Takeda Pharmaceutical Company Limited ...earch & Development Center, Inc., U.S., announ... the U.S. Food and Drug Administration (FDA) recom...eatment of hyperuricemia in patients with gout. Th...ne panel member abstaining. The vote followed pres...
(Date:11/24/2008).../ -- Leaders of Schering-Plough Corporation (NYSE:... the company,s research pipeline, highlighting a r...entities in clinical trials or under regulatory re...search and development is adding strength and brea...mation," said Fred Hassan, chairman and CEO. "Our...
(Date:11/24/2008)... long-term commitment to hepatitis research , ...ll/ -- Schering-Plough Corporation (NYSE: SGP ) ...s lead investigational oral hepatitis C protease i...company believes boceprevir has the potential to b...bitor for treating chronic hepatitis C. The compa...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 1Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 2Kidney cancer drug attacks a major type of acute myeloid leukemia 10430 3Using DNA scientists hunt for the roots of the modern potato 2050 1Using DNA scientists hunt for the roots of the modern potato 2050 2American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 1American Red Cross Launches 2008 National Public Service Advertising Campaign 10429 2Flextronics Announces Third Quarter Results 10427 1Flextronics Announces Third Quarter Results 10427 2Flextronics Announces Third Quarter Results 10427 3Flextronics Announces Third Quarter Results 10427 4Flextronics Announces Third Quarter Results 10427 5Flextronics Announces Third Quarter Results 10427 6Flextronics Announces Third Quarter Results 10427 7Flextronics Announces Third Quarter Results 10427 8Flextronics Announces Third Quarter Results 10427 9Flextronics Announces Third Quarter Results 10427 10Flextronics Announces Third Quarter Results 10427 11Flextronics Announces Third Quarter Results 10427 12Flextronics Announces Third Quarter Results 10427 13Flextronics Announces Third Quarter Results 10427 14Flextronics Announces Third Quarter Results 10427 15Flextronics Announces Third Quarter Results 10427 16Flextronics Announces Third Quarter Results 10427 17Flextronics Announces Third Quarter Results 10427 18Flextronics Announces Third Quarter Results 10427 19
...Calif., June 05, 2007 /PRNewswire/ -- MAP,Pharmace... Phase 2,data from its MAP0004 migraine therapy cl...e Society Meeting at the Hyatt Regency,Chicago in ...was,accepted as a late-breaker, is entitled Rapid ...led Dihydroergotamine Mesylate,via a Novel Inhaler...
...une 05, 2007 /PRNewswire/ -- , Professor Home said...ppointing and,misleading in that they disregarded ...nt to patients and physicians. Most,significantly ...e,of any increase in cardiovascular death or death...T: Professor Philip Home, (44) 778-525-1736 , Ter...
Other Medicine Technology:MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the,American Headache Society Meeting 2
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...
Medicine Products: